Who are Dexpure's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Retevmo, Lenvima, Amitriptyline Oxide, Noltec.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexrabeprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dexpure — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexpure (dexrabeprazole) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton Pump Inhibitors. Area: Gastroenterology.

unknown Proton Pump Inhibitors Proto-oncogene tyrosine-protein kinase receptor Ret Gastroenterology Live · refreshed every 30 min

Target snapshot

Dexpure (dexrabeprazole). Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexpure TARGET	dexrabeprazole		unknown	Proton Pump Inhibitors	Proto-oncogene tyrosine-protein kinase receptor Ret
Retevmo	SELPERCATINIB	Eli Lilly	marketed	Kinase Inhibitor [EPC]	Proto-oncogene tyrosine-protein kinase receptor Ret	2020-01-01
Lenvima	LENVATINIB	Eisai	marketed	Kinase Inhibitor [EPC]	Proto-oncogene tyrosine-protein kinase receptor Ret	2015-01-01
Amitriptyline Oxide	AMITRIPTYLINOXIDE		phase 3		Proto-oncogene tyrosine-protein kinase receptor Ret
Noltec	ILAPRAZOLE		marketed	Proton Pump Inhibitors	Potassium-transporting ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton Pump Inhibitors class)

· 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexpure — Competitive Intelligence Brief. https://druglandscape.com/ci/dexrabeprazole. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing